Propranolol Shortage UK 2026

Quick Answer: Is Propranolol in Shortage?

Yes. The shortage is specific: it affects Propranolol 80mg modified-release capsules and 160mg modified-release capsules. These are the once-daily or prolonged-release capsule forms used by many patients who need smoother coverage across the day. The public CPE/DHSC update says both strengths are out of stock until July 2026.

This does not mean every form of Propranolol is unavailable. The same update says Propranolol 40mg and 80mg immediate-release tablets remain available and can support increased demand. That matters because many patients can be moved from a modified-release capsule to a planned immediate-release tablet schedule, but the timing and dose pattern are not a simple "same number of milligrams once daily" swap for every person.

If you are affected, the practical first step is not to ring every pharmacy in the country. Check how many days you have left, ask your regular pharmacy whether they can obtain your exact capsule strength, and ask whether they have received any current local guidance for switching or staged supply. If the capsule cannot be obtained, contact the prescriber who manages the condition you take Propranolol for.

Current Official Status

The primary shortage source is Community Pharmacy England's Medicine Supply Notification for Propranolol 80mg and 160mg modified-release capsules. It reports MSN/2025/059, a Tier 2 medium-impact supply issue. The March 2026 update extends the shortage position for both modified-release strengths to July 2026.

The NHSBSA Serious Shortage Protocols page was checked for this review on 30 May 2026. It did not list an active Propranolol SSP. That is important because an SSP changes what a community pharmacy can supply under national protocol. Without an active SSP, pharmacies generally need the prescription, prescriber instruction, or local commissioned pathway to support a formulation or dose-pattern change.

SSPs can be issued, amended, withdrawn or extended quickly. The safest wording for patients is therefore: there is no active Propranolol SSP visible on the NHSBSA active list at this review, but ask your pharmacist to check the latest SSP table and local guidance before your medicine is due.

Which Propranolol Forms Are Affected?

The affected forms are the 80mg and 160mg modified-release capsules. These may also be described as sustained-release, prolonged-release, MR, SR, XL or long-acting depending on brand and packaging. The common patient issue is the same: the medicine is designed to release Propranolol slowly over time, so it is usually taken less often than immediate-release tablets.

The CPE/DHSC update says immediate-release Propranolol 40mg and 80mg tablets remain available and can support increased demand. These tablets release the medicine differently and may require a different daily schedule. If your prescription currently says 80mg MR once daily or 160mg MR once daily, do not assume the replacement is one 80mg tablet or two 80mg tablets at the same time. The prescriber needs to decide the safest pattern for your condition and monitoring needs.

The update also says Propranolol oral solution remains available but cannot support increased demand. This is a useful option for some patients who cannot swallow tablets or who need a liquid formulation, but it should not be treated as the default replacement for everyone affected by capsule supply. Oral solution capacity is limited and may be needed for patients with specific formulation needs.

What To Do If Your Capsules Are Out Of Stock

• Count your remaining doses now. If you have fewer than 14 days left, contact the pharmacy and prescriber promptly rather than waiting for the next repeat cycle.
• Ask the pharmacy for exact wording. Ask whether it is the 80mg MR capsule, 160mg MR capsule, brand, wholesaler supply, or local allocation that is unavailable.
• Ask whether any SSP or local guidance is active today. The public NHSBSA page did not show a Propranolol SSP on 30 May 2026, but the pharmacist should check current systems.
• Contact the prescriber if a formulation change is needed. Your GP, cardiology clinic, neurology clinic, endocrine team or mental health prescriber may need to write a new prescription or dosing instruction.
• Do not stop abruptly. Sudden beta-blocker interruption can be risky for some patients, especially those using it for heart rhythm symptoms, angina, migraine prevention, thyroid symptoms or long-term control of physical anxiety symptoms.
• Tell the prescriber why you take it. The best alternative for migraine prevention may not be the same as the best alternative for palpitations, tremor, angina, hypertension or thyroid-related symptoms.

Switching From Modified-Release To Immediate-Release

Modified-release and immediate-release Propranolol are not just different shapes of the same tablet. They deliver the same active medicine, Propranolol hydrochloride, but the release profile is different. Modified-release capsules are designed to release the drug gradually. Immediate-release tablets release it faster and may need to be taken at divided times across the day.

That is why a switch should be written as a plan rather than guessed. A pharmacist or prescriber will consider the current total daily dose, what time you normally take it, your resting heart rate, blood pressure, symptoms, other medicines, and the condition being treated. They may also consider whether you need follow-up after the first few days or weeks of the change.

Patients often notice practical differences after a formulation switch. Some people feel no meaningful difference. Others notice more symptom variation between doses, tiredness, dizziness, sleep disturbance, or breakthrough palpitations or tremor if the timing is not right. These symptoms should be reported, not self-corrected with extra doses.

Alternatives A Clinician May Discuss

The word "alternative" is easy to misuse. For Propranolol, the best alternative depends heavily on why the medicine was prescribed. Propranolol is a non-selective beta blocker and is used across several different clinical contexts. The NHS Propranolol medicines page describes use for heart problems, anxiety symptoms and migraine, while patient leaflets list additional uses such as tremor and some thyroid-related symptoms.

For some patients, the alternative may be a planned move to immediate-release Propranolol tablets. For others, a prescriber may discuss another beta blocker such as atenolol or bisoprolol. That decision depends on the condition, pulse, blood pressure, breathing history, pregnancy or breastfeeding status, and other medicines. People with asthma or wheeze history need particular care because beta blockers can be unsuitable for some patients.

For migraine prevention, a clinician may also consider non-beta-blocker options if Propranolol is no longer suitable or symptoms are not controlled after a formulation change. For anxiety-related physical symptoms, the prescriber may focus on short-term symptom control, dose timing, and whether Propranolol is still the right medicine. For heart rhythm, angina, tremor or thyroid symptoms, specialist advice may be needed before changing class.

Do not use a friend or forum dose as a conversion. A person taking Propranolol for migraine prevention may be on a different target dose and monitoring plan from someone taking it for a heart rhythm condition. The safe action is to get the switch written into your prescription record.

Safety Checks Before Any Change

Before a switch, tell the pharmacist or prescriber if you have asthma, COPD, wheezing, very low blood pressure, slow pulse, fainting episodes, diabetes with frequent hypos, circulation problems, heart block, heart failure that is not stable, pregnancy, breastfeeding, or a recent hospital admission. Also list any other medicines, including verapamil, diltiazem, other blood pressure medicines, anti-arrhythmics, migraine preventives, antidepressants, diabetes medicines and over-the-counter remedies.

The electronic Medicines Compendium patient leaflet for Propranolol tablets explains that Propranolol can interact with other medicines and that patients should talk to a doctor or pharmacist before taking it with other treatment. It also points patients to the MHRA Yellow Card route for side-effect reporting.

Seek urgent medical help if you develop chest pain, severe shortness of breath, fainting, severe dizziness, signs of a serious allergic reaction, or symptoms that feel immediately dangerous. For non-urgent but concerning symptoms after a switch, contact your pharmacist, GP, NHS 111, or the specialist team that manages the condition.

How Long Will The Shortage Last?

The best current public date is July 2026 for both affected modified-release strengths. Supply dates are estimates, not guarantees. Shortage recovery can change because of manufacturing release, batch testing, wholesaler allocation, import decisions, demand shifts and local pharmacy stock cycles.

The national shortage-management process is described in DHSC's medicine supply management guidance on GOV.UK. It explains that DHSC and NHS England assess shortage notifications, issue medicine supply notifications to professionals, use the SPS medicines supply tool, and publish SSPs via NHSBSA where appropriate. In practice, this means a shortage can look different to patients depending on where they live, when their prescription is due, and which wholesaler serves their pharmacy.

If your next repeat is due before July 2026, assume you may still be affected. If the first pharmacy cannot source your capsule, ask whether it is worth checking another branch in the same chain, an independent pharmacy, or the dispensing doctor route if relevant. Keep a note of who you spoke to and what formulation was discussed so the prescriber has clear information.

Why Local Pharmacy Stock Can Differ

National shortage status is not the same as the shelf position in one pharmacy. A medicine can be nationally short while a local pharmacy still has a small amount of old stock. The reverse is also true: a medicine can be nationally available while a particular pharmacy has no stock because of delivery timing, wholesaler allocation, local demand, or prescription volume.

For Propranolol MR capsules, the key question is not only "do you have Propranolol?" It is "do you have my exact strength and modified-release capsule form, and can you obtain enough for my prescription?" A pharmacy may have 40mg immediate-release tablets but no 80mg MR capsules. They may have oral solution but reserve it for patients who cannot use tablets. They may also be able to see wholesaler availability before a patient can.

If you need a same-day solution, be clear and concise: state the exact medicine, strength, formulation, brand if relevant, days remaining, and why you take it. If the pharmacist says a prescriber needs to change the prescription, ask them what wording or formulation they recommend you discuss with the GP or specialist.

Frequently Asked Questions

Sources And Review Method

This page was reviewed for source alignment on 30 May 2026. The shortage status is anchored to the public CPE/DHSC medicine supply notification, checked against the NHSBSA active SSP table, and cross-referenced with NHS and eMC medicine information for patient-safety context. MediWatch does not invent stock claims from pharmacy anecdotes and does not provide individual prescribing advice.